Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides ( 
gp120 that are important in type-specific virus neutralization. The idenfification of these type-specific neutralizing epitopes should facilitate the design of a polyvalent, synthetic vaccine for AIDS.
The human immunodeficiency virus (HIV) is the etiologic agent of the acquired imnmunodeficiency syndrome (AIDS) (1) (2) (3) (4) . AIDS is now a world-wide epidemic for which there is no vaccine or cure. Work toward the development of a vaccine for AIDS has centered on the external envelope glycoprotein of HIV, gpl20. The gpl20 molecule of HIV and recombinant molecules containing amino acid sequences of gp120 have antigenic sites that evoke virus-neutralizing antibody responses in mammals (5) (6) (7) (8) (9) (10) . Among some HIV isolates, there is substantial genomic heterogeneity localized in hypervariable regions of the env gene encoding gpl20 (11) (12) (13) (14) (15) .
Differences in env genes among HIV isolates can be associated with antigenic (16) or structural changes in gpl20 and also can account for the fact that antibodies raised in animals to gp120 frequently neutralize only that isolate (or type) of HIV from which the gp120 is derived (9, 10, 17) .
It has been our approach to use synthetic peptides containing hydrophilic amino acids from both conserved and
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variable regions of HIV gpl20 to identify antigenic sites of gp120 using AIDS patient sera and to evaluate the functional importance of these gp120 epitopes with antipeptide antibodies raised in goats. In this study we (19) of HTLV-IIIB gpl2O were determined as described. Amino acid sequences of HTLV-IIIB (ref. 20 , clone BH10) envencoded synthetic peptides used in this study are SP-1, SP-10-IIIRF(A) contains the following amino acid sequence from HIV-isolate HTLV-IIIRF gpl20: (Cys)-Arg-Lys-SerIle-Thr-Lys-Gly-Pro-Gly-Arg-Val-Ile-Tyr (14) . Amino acids in parentheses were added to facilitate iodination (Tyr) of the peptides or coupling to carrier protein (Cys). A control peptide from the COOH terminus of HTLV-I gp45 was also used: SP-70A, (Tyr)-Pro-Pro-Phe-Ser-Leu-Ser-Pro-Val-ProThr-Leu-Gly-Ser-Arg-(Cys). After synthesis, peptides were deprotected and cleaved from the supporting resin with (21) . Conjugation of peptides to carrier proteins was monitored by trace iodination of peptide or by estimating the molecular weights of conjugates subjected to NaDodSO4/ PAGE as described (22) . Sequencing of SP-10-IIIB and amino acid analysis of SP-10C-IIIB confirmed the amino acid content of these peptides. Antisera. Antisera to peptide conjugates were raised in goats by subcutaneous immunization in two sites at day 0 with 28 mg of conjugate suspended in 1 cc of complete Freund's adjuvant followed by booster immunizations approximately every 2 weeks for 2-3 months in incomplete Freund's adjuvant. Serum was collected before immunization and 2 weeks after boosting.
Immunoassays. Binding of antibodies from HIV-seropositive subjects or from immunized animals to env-encoded synthetic peptides in RIA was determined as previously described (22) . Immunoblotting (23) and radioimmunoprecipitation (RIP, ref. 22 ) assays were done as previously described.
Neutralization and Syncytium Formation Assays. HIV neutralization assays were done as described (9) CEM cells infected with HTLV-IIIB or HTLV-IIIRF with or without anti-gpl20 antibodies as described (10) . After incubation (24 hr, 37°C in 5% C02/95% air), the number of giant cells in duplicate wells was determined by microscopic exam- ination ( x 40 magnification).
RESULTS
HIV Patient Antibody Reactivity to Synthetic Peptides from HTLV-IB gpl2O. Sera from AIDS patients (n = 12) were tested in RIA for antibody reactivity to synthetic peptides SP-1, -10, -1OA, -11, -14, -15, and -22 containing hydrophilic amino acid sequences from HTLV-IIIB gpl2O (Fig. LA) . Six of 12 sera (50%) reacted with peptide SP-10 by greater than three times the mean control cpm value obtained with normal human serum controls (n = 4). By the same criterion, 7 of 12 sera had positive reactivity to peptide SP-22 from the COOH terminus of gpl20 (22), used here as a positive control. To determine the reactivity of large numbers of AIDS patient sera with SP-10, a more extensive screen of 175 sera from HIV-seropositive individuals was undertaken. We found that 21% of seropositive subjects had positive reactivity to SP-10-I"'B in RIA (data not shown).
To evaluate further the reactivity of AIDS patient antibodies to synthetic peptide SP-10-1'B, an affinity column containing BSA-peptide conjugate SP-10-IIIB was used to isolate peptide-specific anti-gpl20 antibodies from 2-ml aliquots of an AIDS patient serum with antibody reactivity to SP-10. Affinity columns containing equal amounts of synthetic peptides SP-1OA, -11, -14, -15, and -22 coupled to BSA were used as controls. Antibodies eluted from affinity columns with 4 M MgCl2 and dialyzed were tested for reactivity to HTLV-IIIB env-encoded synthetic peptides in RIA and 1251I-labeled gp120-"IIB in RIP assay. Antibodies recovered from SP-10-"'B' SP-10A-IIIB, and SP-22-IIIB affinity columns reacted specifically with the corresponding peptide in RIA but not to other env-encoded synthetic peptides (data not shown). When itated I251-labeled gpl20-III (Fig. 1B) , whereas eluates from affinity columns containing SP-11, -14, and -15 did not. In addition, affinity-purified human anti-SP-10-IIIB antibodies bound to the surface of H9 cells infected with HTLV-IIIB in indirect immunofluorescence assay using flow cytofluorometry (data not shown). Because of data indicating that AIDS patient antibodies bound to SP-10, we next evaluated the ability of SP-10 to evoke a neutralizing antibody response in animals.
Goat Antisera to SP-10-1IB Bound to gpl2O-IIB. HTLV-IIIB env-encoded synthetic peptide SP-10-IIIB conjugated to TT was used to raise antisera to gp12O-IIIB in two goats.
Antisera and preimmune serum controls were then evaluated in three assays: RIA for antipeptide reactivity, immunoblotting assays for reactivity to gp120, and indirect immunofluorescence using flow cytofluorometry for antibody binding to the surface of HIV-infected cells. Goat antiserum raised to SP-1O-IIIB reacted specifically with SP-10-IIIB conjugated to BSA in RIA but not to the gpl20 COOH-terminal peptide SP-22-BSA used as a negative control (data not shown). (Table 1) . In contrast, anti-SP-10-IIIB antisera did not neutralize HTLV-IIIRF or HTLV-IIIMN or inhibit syncytium formation by these isolates. Conversely, goat antiserum to peptide SP-10-IIIRF(A) containing an homologous amino acid sequence from HIV isolate HTLV-IIIRF, gp120 inhibited syncytium formation by HTLV-IIIRF, but had no effect on syncytium formation induced by HTLV-IIIB or HTLV-IIIMN. Control antisera raised to synthetic peptide SP-22-IIIB-TT conjugate containing a conserved amino acid sequence from the COOH terminus of HTLV-IIIB gp120 had no effect on the ability ofthe three HIV isolates to infect H9 cells (Table 1) 
DISCUSSION
In this study we describe the use of env-encoded synthetic peptides coupled to TT to raise high titers of isolate-specific, anti-HIV neutralizing antibodies. Goat antisera were raised in two goats to synthetic peptide SP-10-IIIB' containing at the COOH terminus an amino acid sequence from a hydrophilic, hypervariable region of HTLV-IIIB gpl20. Sera from both goats neutralized HTLV-IIIB and inhibited HTLV-IIIBinduced syncytium formation but did not inhibit infection of T cells with HIV isolates HTLV-IIIRF or HTLV-IIIMN. Moreover, when six amino acids (Thr-Arg-Pro-Asn-AsnAsn) from the NH2-terminal region of SP-10-IIIB were deleted, the resulting synthetic peptide (SP-10C-IIIB) also induced type-specific antibodies that neutralized only HTLV-"'B as determined by inhibition of syncytial cell formation (Table 1) . These six NH2-terminal amino acids of SP-10-IIIB are highly conserved among HIV isolates, whereas the COOH-terminal sequence of SP-10-IIIB is highly variable. Thus, deletion of a conserved region at the NH2 terminus of SP-10-IIIB would not be expected to abolish the ability of peptide SP-10C-IIIB to evoke a type-specific antibody response to HTLV-IIIB. Also, the homologous peptide SP-10-IIIRF(A) containing an amino acid sequence derived from HTLV-IIIRF gpl20 elicited antibodies that blocked syncytium formation by isolate HTLV-IIIRF but not by HTLV-1934 Immunology: Palker et al. Syncytium induction by HIV is mediated by the interaction of the CD4 molecule with gpl20 on the surface of cells (27) (28) (29) (30) (31) (32) (33) . Because antibodies directed to the SP-10 region of gpl20 inhibited syncytium induction by HIV, the SP-10 region of gpl20 must either contain or be closely associated with sites of gpl20 that interact with the CD4 molecule. Recently, two groups (33, 34) responses to HIV will require primed preexisting T-cell as well as B-cell responses, it will be important to covalently link SP-10-like peptides to peptides containing appropriate helper T-cell epitopes and to evaluate these conjugates for their ability to induce anti-HIV neutralizing antibodies and, as well, to induce HIV-specific T-cell responses in primates.
